Thymosin Alpha 1 Melanoma Trial: What It Found

The thymosin alpha 1 melanoma trial did not establish that adding thymosin alpha-1 helped people live longer. Some treatment groups had more tumors shrink. Its 488 participants had melanoma, a skin cancer, that had spread. Everyone received cancer medicines; thymosin alpha-1 was never tested alone.

Two groups reached the study's preset target for tumor shrinkage. That justified further study. It did not establish a replacement for cancer care or a benefit for everyday immunity.

What did the thymosin alpha 1 melanoma trial ask?

Could thymosin alpha-1 improve results when combined with older melanoma medicines? Thymosin alpha-1 is a peptide, a short chain of protein building blocks. Thymalfasin is its medicine name.

Maio and colleagues' 2010 Journal of Clinical Oncology paper describes a phase 2 trial, an exploratory test of treatment activity. All five groups received dacarbazine, a chemotherapy drug that damages cancer cells. Four also received interferon alfa, a medicine that changes immune signaling.

Chance determined treatment assignments. The comparison group received dacarbazine plus interferon, without thymalfasin. There was no placebo, an inactive comparison preparation. The trial registry, NCT00911443, confirms the five combinations.

Who joined, and what was measured?

Researchers enrolled 488 adults at 64 European centers between 2002 and 2006. Average ages across groups were 54–57. Participants had cancer that surgery could not remove and at least one measurable tumor.

Eligibility excluded prior chemotherapy, brain metastases, meaning cancer spread to the brain, and melanomas originating in the eye or internal linings. The registry also excluded autoimmune disease, where immunity attacks the body's own tissues, and transplant recipients.

Treatment lasted up to six 28-day cycles. Tumor response was followed for 12 months and survival for up to 24 months.

The primary endpoint, the main result selected for the trial, was best overall tumor response. Independent reviewers who did not know treatment assignments assessed scans. A response meant complete disappearance or sufficient shrinkage under RECIST, standardized rules for measuring tumors. It did not mean the cancer could never return.

The response results, arm by arm

About 12 in 100 people responded in the thymalfasin-plus-dacarbazine group, compared with four in 100 controls. The two middle-dose groups met the study's benchmark of at least nine responses.

Here, D means dacarbazine, I means interferon and T means thymalfasin. The milligram amounts identify trial groups, not personal dosing instructions. Median survival estimates when half a group has died. A 95% confidence interval gives the uncertainty range around that estimate.

These are Table 2's results. The benchmark tested each arm against an expected response rate of 5%. In the analysis including everyone randomized, response rates did not differ significantly between treatment groups.

The study changed during enrollment, adding the highest-dose arm after an early look at results. The authors acknowledged that this weakened planned comparisons between groups. The response counts therefore support another trial, not a settled treatment benefit.

Did people live longer?

Survival estimates were numerically longer in the peptide groups, but a survival advantage was not established. Survival was a secondary outcome, an additional measurement rather than the main test.

The authors' exploratory analysis combined all four peptide groups: median survival was 9.4 months versus 6.6 months in controls. The hazard ratio, which compares death rates over time, was 0.80. Its 95% confidence interval was 0.63–1.02, including 1, the value for equal rates. The P value was 0.08, above the study's threshold for a statistically clear difference.

Those pooled numbers do not describe one dose or combination. Median progression-free survival, time before worsening, new cancer treatment or death, ranged from 1.8 to 2.0 months across arms.

What did the side-effect table show?

Almost everyone had an adverse event, a medical problem recorded during the study. That does not mean thymalfasin caused it. Participants had advanced cancer and received other drugs.

Table 3 used the people who received treatment, so two denominators differ from the response table:

Nausea, vomiting, fever and fatigue appeared in the detailed symptom table. The authors reported no added overall toxicity from thymalfasin. That does not mean zero serious harm: treatment-related serious events occurred across the combinations, and 11 such events led to death. Attribution concerned the treatment regimen, not thymalfasin alone.

What did later research and reviewers add?

A 2018 follow-up by Danielli and colleagues reviewed records of patients who later received ipilimumab, an immune treatment. Longer survival in selected patients did not establish that earlier thymalfasin caused it. Treatment selection and surviving long enough to receive another medicine can distort that comparison.

FDA's November 15, 2024 review questioned whether the melanoma study established thymalfasin's contribution to the combinations. It also emphasized how much cancer care had changed.

As of November 5, 2026, the day this article was written, a 2026 conference abstract describes 19 older adults receiving thymosin alpha-1 with toripalimab, another immune treatment. It had no comparison group and is an early report, not confirmation of the older randomized trial.

The NCI melanoma treatment summary lists checkpoint inhibitors, medicines that release brakes on immune cells, and treatments targeting specific cancer changes. The older chemotherapy combinations cannot stand in for those options.

The 2025 TESTS trial in BMJ found no clear survival benefit in sepsis, a life-threatening response to infection. The sepsis-trial guide covers that separate question. Immune signaling cannot substitute for outcomes in the disease being treated; the broader benefits guide explains that distinction across conditions.

What does this mean for a compounded prescription?

The study did not compare a compounded prescription with its study medicine. Matching a molecule's name does not establish matching effects or safety. The U.S. regulatory record is a separate question from this trial's results.

As of November 5, 2026, the day this article was written, HHS's October 30 Federal Register notice announces a nonbinding draft peptide-compounding policy. Thymosin alpha-1 is absent from its six-peptide Appendix A; the HHS policy explainer covers the conditions.

Thymosin alpha-1 prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, prepared for an individual prescription, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor.

What belongs in the provider conversation?

The useful questions concern the intended goal, current cancer treatment, other medicines and whether the evidence fits the person's situation. Cancer-treatment decisions belong with the treating oncology team. A peptide trial from the chemotherapy era does not supply a reason to replace that care.

At Promise, a licensed provider reviews every request, and not everyone qualifies. If prescribed, the provider sets the individual dose and follow-up.